Mucinous Cystadenocarcinoma of the Pancreas with Cyst Infection in a Male Patient

Ko Tomishima¹², Toshio Fujisawa¹, Yuki Fukumura¹, Mako Ushio¹, Sho Sato², Nozomi Amano², Ayato Murata², Hironori Tsuzura², Shunsuke Sato², Kouhei Matsumoto¹², Yuji Shimada³, Takuya Genda² and Hiroyuki Isayama¹

Abstract:
Follow-up computed tomography revealed a 40-mm pancreatic tail cyst in a 59-year-old man with type 1 diabetes mellitus. An intraductal papillary mucinous neoplasm was suspected; mucinous cystic neoplasm (MCN) was not considered because the patient was a man. During follow-up, cyst infection occurred but was improved by conservative treatment. At the 24-month follow up examination, cyst nodules had developed, corresponding to an increase in the carbohydrate antigen 19-9 level. Mucinous cystadenocarcinoma (MCC) was diagnosed pathologically based on distal pancreatectomy. A diagnosis of male MCN/MCC is often delayed, which may lead to a poor prognosis. MCN infection is also rare and poorly recognized. We observed an atypical male case of MCN/MCC.

Key words: pancreatic cancer, MCN, MCC, cyst in cyst, male

(Intern Med 59: 2383-2389, 2020)
(DOI: 10.2169/internalmedicine.4937-20)

Introduction
Mucinous cystic neoplasm (MCN) of the pancreas was first reported by Compagno et al. in 1978 (1). MCN is a relatively rare pancreatic cyst tumor that accounts for 2-5% of exocrine tumors and is predominately found in the body and tail of the pancreas in middle-aged women (2). Morphologically, MCN shows both unilocular and multilocular lesions with a thick fibrous capsule. A small cyst inside the main cyst is observed, which is referred to as “cyst in cyst.” This is a useful feature for diagnosing MCN morphologically based on imaging studies. Regarding the pathology of MCN, ovarian-like stroma positive for estrogen receptor (ER) and progesterone receptor (PgR) is mandatory for the diagnosis. As such, MCN is very rare in men. Surgical resection is recommended in all cases of MCN because adenocarcinoma frequently occurs (3). However, a preoperative diagnosis of atypical cases, such as in men and cases of cyst infection, may be more difficult.

Case Report
We herein report a 59-year-old man with mucinous cystadenocarcinoma (MCC). His medical history included type 1 diabetes mellitus, angina pectoris, calculous cholecystitis, and acute pancreatitis due to alcohol consumption. His drinking history consisted of 700 mL of beer daily. There was no history of smoking or allergy. He had no symptoms at the initial diagnosis, and a blood test revealed only slight anemia (Table 1). Computed tomography (CT) revealed a 40-mm multi-locular cyst on the pancreatic tail that did not contain an intra-cystic nodule or cyst. The cysts were adjacent to each other in a “cyst by cyst” manner, so it was diagnosed as an intraductal papillary mucinous neoplasm (IPMN) and followed (Fig. 1).

One year and 7 months after the initial diagnosis, cyst infection was suspected due to the presence of abdominal pain and peri-cystic fat stranding on CT (Fig. 2). The cyst infection improved through conservative treatment with antibiot-
tics, and the patient was discharged on day 15. Although the cyst had not changed in diameter at two years and two months after the initial diagnosis, two new nodules were found inside the cyst. The nodules showed a low intensity on both T1- and T2-weighted magnetic resonance imaging (MRI) images and high intensity on diffusion-weighted imaging (DWI) (Fig. 3). Magnetic resonance cholangiopancreatography (MRCP) revealed no dilatation of the main pancreatic duct, which did not communicate with the cyst. A 13-mm nodule was found inside the cyst by contrast-enhanced abdominal ultrasonography (Fig. 4). Furthermore, the level of carbohydrate antigen (CA) 19-9 had also increased over time, and malignancy could not be ruled out (Fig. 5). A diagnosis of IPMC was considered preoperatively, and lymphoepithelial cyst (LEC), epidermoid cyst and dermoid cyst were considered as differential diagnoses. Pancreatic mucinous neoplasm was considered unlikely because the patient was a man.

After obtaining the patient’s informed consent, distal pancreatectomy was performed two years and two months after the initial diagnosis. A macroscopic examination of the surgical specimen revealed a 32×28-mm cyst containing a papillary nodule (Fig. 6A). The cyst contained a copious amount of mucin, suggesting MCN or IPMN macroscopically. The level of mucus amylase was normal at 63 U/L, but the CA19-9 level in the cyst was high at 521 U/mL. Microscopically, the cyst had thick fibrous wall and a papillary-growing tumor inside (Fig. 6B). The tumor cells exhibited eosinophilic cytoplasm with irregularly spaced, enlarged and roundish nuclei (Fig. 6D). The tumor invasion was observed as tubular adenocarcinoma (Fig. 6E, F). The cyst wall contained abundant spindle-shaped stromal cells growing in fascicles, which were immunohistochemically positive for ER, PgR and smooth muscle actin (SMA), suggesting that they were ovarian-like stroma (Fig. 7). We also conducted a somatic mutation analysis of G-protein αs (GNAS) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), as described previously (4). We analyzed

| Table 1. Laboratory Data. |
|---------------------------|
| Biochemistry              | Complete blood count |
| Alb (g/dL)                | WBC (10⁹/μL)          | 7.2 |
| BUN (mg/dL)               | RBC (10⁹/μL)          | 441 |
| Cre (mg/dL)               | Hb (g/dL)             | 12.9 |
| eGFR (mL/min)             | CA19-9 (U/mL)         | 9   |
| Na (mM/L)                 | CEA (ng/mL)           | 4   |
| Cl (mM/L)                 | DU-PAN-2 (U/mL)       | 27  |
| K (mM/L)                  | SPAN-1 (U/mL)         | 15.6 |
| γGTP (IU/L)               |                        |     |

Alb: albumin, BUN: blood urea nitrogen, Cre: creatinine, eGFR: estimated glomerular filtration rate, Na: sodium, Cl: chlorine, K: potassium, ALT: aspartate aminotransferase, ALT: alanine aminotransferase, γGTP: γ-glutamyl transpeptidase, WBC:white blood cell, RBC: red blood cell, Hb:hemoglobin, Plt: platelet, CA19-9: carbohydrate antigen 19-9, CEA: carcinoembryonic antigen, DUPAN-2: dupe pancreatic monoclonal antigen type 2, Span-1: s-pancreas-1 antigen

Figure 1. Initial CT images showing a 40-mm multilocular cyst on the pancreatic tail. A) Unenhanced CT image showing a multilocular cyst on the pancreatic tail. B) Arterial-phase CT image showing a multilocular cyst with no enhancement. C, D) Venous-phase CT image showing a multilocular cyst with slight contrast enhancement of the cyst septa.
the tumor cells of the papillary nodule using a pair of primers (i) for exon 8 of \textit{GNAS}: TTGGTGAGATC-CATTGACCTCAATTT (left) and TGAATGTCAGAAAC-CATGATCTCTGT (right), (ii) for exon 9 of \textit{GNAS}: GAA-GATTCACCAGCTCCCTCTGG (left), GAACAGCCAAAG CCCACAGCA (right), and (iii) for exon 2 of \textit{KRAS}: CTGG TGGAGTATTTGATAGT (left), CTCATGAAATGGTCAG AGAAACCT (right). It was revealed that this tumor was \textit{GNAS} wild and \textit{KRAS} mutated (G12D). These findings led to a diagnosis of invasive MCC of the pancreas (pT1bN0M0, stage IA).

The patient was followed for 10 months after resection; during this period, recurrence did not occur. This study was approved by the Ethics Committee of Juntendo University, Tokyo, Japan, on August 2018 and was performed according to the Declaration of Helsinki.
Discussion

MCNs are multilocular mucin-producing tumors that tend to differentiate into gastric, intestinal, bile duct and pancreatic epithelia. The World Health Organization (WHO) defines MCNs as tumors with ovarian-like stroma in a thick cyst wall (5). Epidemiologically, MCNs often occur in the body and tail of the pancreas in women 40-50 years old (6). A few male cases of MCN (approximately 0-8.5% of all cases) have been reported (7-10). Regarding the malignant potential, a large cyst diameter and the presence of nodules therein have been identified as risk factors for malignant transformation of MCN (7). A review of surgically resected and unresected cases indicated that cysts less than 40 mm in size not containing a mural nodule tended to be considered benign and so were observed rather than resected (11, 12). However, the literature regarding MCNs should be interpreted with caution, as MCNs and IPMNs were considered to be the same entity before the International Consensus Guidelines were published in 2006 (13).

Fifteen male cases of MCN have been reported in PubMed, including the present case (Table 2) (7, 14-23). The mean age was 49 years, all cysts were located in the body and tail of the pancreas, and all had ovarian-like stroma. The mean size of the cysts was 45 mm, and 2 cysts (14%) had components of microinvasive carcinoma. Although there are few male cases of MCN in the literature, Ethun et al. reported a rate of adenocarcinoma and high-grade dysplasia in these cases of 39%, which is higher than that in women (24). They also speculated that the low detection rate of male MCN might be attributed to its high malignant potential in men (24). The mean tumor size in male cases of MCN, including the present patient, is 45 mm, which is smaller than that for all of the MCN cases reported by Yamao et al. (7).

Our patient was a middle-aged man, and the cyst was located in the tail of the pancreas. Additionally, the cyst di-
Figure 6. Pathological findings. (A) The resected pancreas cyst revealed a papillary and whitish nodule inside (arrow). (B, C) Microscopically, the cyst had relatively thick fibrous wall and a nodule inside (B: original magnification ×12.5, C: Loupe image). (D) A closer view showed a papillary-growing tumor inside the cyst (original magnification ×100). (E, F) Invasive tubular adenocarcinoma was associated with MCN (arrowheads) (E: original magnification ×12.5, F: original magnification ×100). B-F: Hematoxylin and Eosin staining. MCN: mucinous cystic neoplasm

Figure 7. Ovarian-like stroma. Spindle-shaped stromal cells were seen at the cyst wall and septum (A) and were immunohistochemically positive for SMA (B), ER (C) and PgR (D). A: Hematoxylin and Eosin staining, B: immunohistochemistry for SMA, C: immunohistochemistry for ER, D: immunohistochemistry for PgR (A-D: original magnification, ×100). SMA: smooth muscle actin, ER: estrogen receptor, PgR: progesterone receptor

The diameter did not increase over time, but nodules appeared on the cyst wall after the cyst had become infected. This case had an atypical clinical course due to the absence of a thick capsule-like ovarian-like stroma on CT and the occurrence of cyst infection. Furthermore, the tumor size did not increase over time and, because the patient was male, we did
In the present case. However, Sandrasegaran et al. reported intensity of DWI helped diagnose some nodules in the cyst/c033 in MCN cases involving pancreatic duct dilation, a cyst size ultrasound-guided fine needle aspiration (EUS-FNA) is used. IPMN and MCN are not distinguished. Endoscopic can Gastroenterological Association (AGA) guidelines, diameter can be closely observed instead (29). In the Ameri-surgery is the treatment of choice, tumors <40 mm in di-

cation of the International Association of Pancrea-

to the guidelines of the International Association of Pancrea-

We considered three sets of international guidelines per-

taining to the treatment of male cases of MCN. According to the guidelines of the International Association of Pancreato-

not suspect MCN. In rare cases of a large size tumor and
cyst infection, drainage or surgical resection is typically em-
plored, but this case improved with antibiotic therapy. Re-
garding IPMNs, cyst infection may indicate high-grade dys-
pasia, where an association between symptom severity and
malignancy of IPMN has been demonstrated (25). Although
inflammatory reactions can be identified based on an ele-

Table 2. Fifteen Cases of Male MCNs have been Reported in PubMed Including This Case.

| Reference numbers | Age  | Location | Diameter (mm) | Clinical Symptoms | Preoperative Diagnosis | Surgical Procedure | Histopathology | CA19-9 U/mL (serum) |
|-------------------|------|----------|--------------|-------------------|------------------------|--------------------|---------------|-------------------|
| 14                | 43   | Tail     | 40           | Weight Loss       | Pseudocyst             | SPDP               | Adenoma        | N/A               |
| 15                | 73   | Tail     | 60           | no                | Epidermoid Cyst        | DP                 | Adenoma        | N/A               |
| 16                | 25   | Tail     | 50           | Abdominal Pain    | BD-IPMN                | DP                 | Adenoma        | 2                 |
| 17                | 28   | Body-Tail | 40           | Abdominal Pain    | PDAC                   | SPDP               | Adenoma        | N/A               |
| 18                | 39   | Tail     | 63           | Back Pain         | BD-IPMN                | DP                 | Adenoma        | N/A               |
| 19                | 26   | Body-Tail | -            | -                 | -                      | DP                 | Adenocarcinoma, invasive | N/A               |
| 20                | 36   | Body-Tail | -            | -                 | -                      | DP                 | Adenoma        | N/A               |
| 21                | 65   | Body-Tail | 49           | None              | BD-IPMN                | DP                 | Adenoma        | N/A               |
| 22                | 48   | Tail     | 47           | None              | Cystic Tumor           | DP                 | Adenoma        | N/A               |
| 23                | 55   | Tail     | 30           | Appetite Loss     | BD-IPMN                | DP                 | Adenoma        | 1.505             |
| 24                | 50   | Tail     | 51           | None              | BD-IPMN                | DP                 | Adenoma        | N/A               |
| 25                | 73   | Tail     | 25           | None              | LEC                    | Spleen-Preserving DP SSPPD | Adenoma        | 156               |
| 26                | 51   | Tail     | 40           | None              | IPMN                   | DP                 | Adenocarcinoma, invasive | 249               |

SPDP: spleen-preserving distal pancreatectomy, DP: distal pancreatectomy, BD-IPMN: branch-duct intraductal papillary mucinous neoplasm, PDAC: pancreatic ductal adenocarcinoma, LEC: lymphoepithelial cyst, SSPPD: subtotal stomach preserving pancreatoduodenectomy, N/A: not applicant

that the apparent diffusion coefficient (ADC) alone was not found to be useful for differentiating malignant from non-
malignant lesions or IPMN from MCN (31). Additionally,
that study included only nine cases of MCN; therefore, a
large-scale study limited to MCN cases is needed. Recently,
a multicenter Japanese study reported 5 factors with the pot-
tential to predict malignancy in MCN: age ≥56 years old,
high serum carcinoembryonic antigen (CEA) and CA19-9
levels, tumor size ≥51 mm, and the presence of mural nod-
ules (32). Regarding atypical cases of MCN, especially
those involving men or small-sized nodules, a diagnosis us-
ing the IAP and ESMO guidelines is difficult. An early di-
gnosis is more important in men than in women because the rate of invasive carcinoma is higher in men than in
women. In cases that are difficult to diagnose by imaging,
EUS-FNA can be used, as described in the AGA guidelines;
for this reason, the use of this diagnostic modality may in-
crease in the future (30). The CA19-9 level in the cyst was
high in this case; such tumor markers in the cyst fluid, as
revealed by EUS-FNA, may facilitate the diagnosis (22).

The management of this case was complicated by not per-
foming EUS or an EUS-FNA examination at the time of
the initial diagnosis, as it is difficult to detect the cyst-in-
cyst structure using other modalities. In Japan, most pancre-
atic cystic lesions are diagnosed based on imaging studies to
avoid tumor cell dissemination.

In conclusion, we encountered a male case of MCN
showing an atypical clinical course, including infection. The
patient showed a poor prognosis due to the delayed diagno-
sis. The infection suggested a malignant lesions similar to IPMN.

The authors state that they have no Conflict of Interest (COI).

References

1. Compagno J, Oertel JE. Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathological study of 41 cases. Am J Clin Pathol 69: 573-580, 1978.

2. Suzuki A, Atomi Y, Sugiyama M, et al. Cystic neoplasm of the pancreas: a Japanese multistitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 28: 241-246, 2004.

3. Yamao K, Nakamura T, Suzuki T, et al. Endoscopic diagnosis and staging of mucinous cystic neoplasms and intraductal papillary-mucinous tumors. J Hepatobiliary Pancreat Surg 10: 142-146, 2003.

4. Mamat O, Fukumura Y, Saiito T, et al. Fundic gland differentiation of oncocytic/pancreatobiliary subtypes of pancreatic intraductal papillary mucinous neoplasm. Histopathology 69: 570-581, 2016.

5. Klöppel G, Solcia E, Longnecker DS, Capella C, Sobin LH. Histological Typing of Tumors of the Exocrine Pancreas. WHO, Ed. Springer, Berlin, 1996: 7-9.

6. Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12: 183-197, 2012.

7. Yamao K, Yamagishowa A, Takahashi K, et al. Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma: a multi-institutional study of the Japanese pancreas society. Pancreas 40: 67-71, 2011.

8. Jang KT, Park SM, Basturk O, et al. Clinicopathological characteristics of 29 invasive carcinomas arising in 178 pancreatic mucinous cystic neoplasms with ovarian-type stroma: implications for management and prognosis. Am J Surg Pathol 39: 179-187, 2015.

9. Gill E, Choi SH, Choi DW, Heo JS, Kim MJ. Mucinous cystic neoplasms of the pancreas with ovarian stroma. ANZ J Surg 83: 985-990, 2013.

10. Crippa S, Salvia R, Warshaw AL, et al. Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg 247: 571-579, 2008.

11. Tajiri T, Tate G, Inagaki T, et al. Mucinous cystadenoma of the pancreas 17 years after excision of gallbladder because of a choledochal cyst. J Gastroenterol 39 (2): 181-187, 2004.

12. Crippa S, Salvia R, Warshaw AL, et al. Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg 247: 571-579, 2008.

13. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6: 17-32, 2006.

14. Wouters K, Ectors N, Van Steenbergen W, et al. Pancreatic mucinous cystadenoma in man with mesenchymal stroma, expressing estrogen and progesterone receptors. Virchows Arch 432: 187-189, 1998.

15. Reddy RP, Smyrk TC, Zapiach M, et al. Pancreatic mucinous cystic neoplasm defined by ovarian stroma: demographics, clinical features, and prevalence of cancer. Clin Gastroenterol Hepatol 2: 1026-1031, 2004.

16. Hifumi M, Fukuda S, Yamane T, et al. A case of pancreatic mucinous cystadenoma in a man with ovarian-type stroma, expressing estrogen and progesterone receptors. Nihon Shokakibyo Gakkai Zasshi (Jpn J Gastro-enterol) 102: 1188-1193, 2005 (in Japanese).

17. Suzuki M, Fujita N, Onodera H, et al. Mucinous cystic neoplasm in a young male patient. J Gastroenterol 40: 1070-1074, 2005.

18. Goh BK, Tan YM, Kumarasinghe MP, Ooi LL. Mucinous cystic tumor of the pancreas with ovarian-like mesenchymal stroma in a male patient. Dig Dis Sci 50: 2170-2177, 2005.

19. Tokuyama Y, Osada S, Sanada Y, Takahashi T, Yamaguchi K, Yoshida K. Mucinous cystic neoplasm of the pancreas in a male patient. Rare tumors 3: e14, 2011.

20. Riccardo C, Pazzilli R, Calcutti L, et al. Pancreatic mucinous cystic neoplasm in a male patient. JOP 13: 687-689, 2012.

21. Fallahzadeh MK, Zibari GB, Wellman G, Abdehou ST, Shokouh-Amiri H. Cystic neoplasm of pancreas in a male patient: a case report and review of the literature. J La State Med Soc 166: 67-71, 2014.

22. Park JW, Jang JY, Kang MJ, Kwon W, Chang YR, Kim SW. Mucinous cystic neoplasm of pancreas: is surgical resection recommended for all surgically fit patients? Pancreatology 14: 131-136, 2014.

23. Tamura S, Yamamoto H, Ushida S, Suzuki K. Mucinous cystic neoplasm in male patients: two cases. Rare Tumors 9: 7096, 2017.

24. Ethan CG, Postlewait LM, McNinis MR, et al. The diagnosis of pancreatic mucinous cystic neoplasm and associated adenocarcinoma in men: an 8-institution study of 349 patients over 15 years. J Surg Oncol 115: 784-787, 2017.

25. Sugiyama M, Izumisato Y, Abe N, Masaki T, Mori T, Atomi Y. Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg 90: 1244-1249, 2003.

26. Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 3: 92ra66, 2011.

27. Khalid A, Finkelstein S, McGrath K, et al. Molecular diagnosis of solid and cystic lesions of the pancreas. Gastroenterol Clin North Am 33: 891-906, 2004.

28. Wu J, Jiao Y, Dal Molin M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA 108: 21188-21193, 2011.

29. Del Chiaro M, Verbeke C, Salvia R, et al. European consensus statement on cystic tumours of the pancreas. Dig Liver Dis 45: 703-711, 2013.

30. Vege SS, Ziring B, Jain R, et al. American gastroenterology association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 148: 819-822; quiz812-813, 2015.

31. Sandrasegaran K, Akisik F.M, Patel A.A, et al. Diffusion-weighted imaging in characterization of cystic pancreas lesions. Clin Radiol 66: 808-814, 2011.

32. Ohtsuka T, Nakamura M, Hijjoka S, et al. Prediction of the probability of malignancy in mucinous cystic neoplasm of the pancreas with ovarian-type stroma: a nationwide multicenter study in Japan. Pancreas 49: 181-186, 2020.